NJ Panel Refuses To Revive Fosamax 'Jaw Death' Suit

Law360, New York (March 25, 2013, 6:17 PM EDT) -- A New Jersey appeals court on Monday refused to revive the case of a woman who claimed Merck Sharp & Dohme Corp.'s osteoporosis drug Fosamax caused her to develop osteonecrosis of the jaw after a tooth extraction, rejecting her argument that the trial judge had wrongly excluded evidence.

A three-judge panel of the New Jersey Appellate Division said the trial judge properly excluded a 2010 Fosamax warning label, finding state rules barred using evidence of remedial measures taken immediately after an event to prove culpable conduct...
To view the full article, register now.